• Accueil >
  • Publications >
  • Using a dose‐finding benchmark to quantify the loss incurred by dichotomization in Phase II dose‐ranging studies

Using a dose‐finding benchmark to quantify the loss incurred by dichotomization in Phase II dose‐ranging studies

1 nov. 2020Biometrical Journal

DOI : 10.1002/bimj.201900332

Auteurs

Pavel Mozgunov, Thomas Jaki, Xavier Paoletti